Clinical Trials Logo

Clinical Trial Summary

Lung cancer is one of the most common malignant tumors in the world and with the highest incidence in China. Surgery is the most effective therapeutic method for primary lung cancer. Accurate prediction of residual postoperative pulmonary function in patients, especially those with borderline pulmonary function, is crucial for proper qualification for surgery. According to the 3rd American College of Chest Physicians(ACCP) evidence-based clinical practice guideline (2013), both predictive postoperative (ppo) FEV1.0% and ppoDLCO% are greater than 60% predicted are required as a first standard of lobectomy for patients with primary lung cancer. And, according to the British Thoracic Society (BTS) guideline, patients with ppoFEV1.0% and ppoDLco% less than 40% have high a risk for surgery. Pulmonary ventilation / perfusion SPECT/CT has recently become available for prediction of lung function, and it can be used to forecast pulmonary function in consideration of the pulmonary circulation as well as effective residual lung function. Traditionally, prediction of postoperative lung function was based on planar method in anterior and posterior projections of lung scintigraphy. However, SPECT/CT enables measurement of ventilation / perfusion uptake in each lobe of the lungs in a three dimensional way, which may avoid underestimating ppoFEV1.0% and provide confidence in suggesting lobectomy or pneumonectomy.

This experiment is intended to explore the use of Q.lung, a volume-based software to semi-quantitatively calculate pulmonary ventilation/perfusion functional uptake and volume by SPECT/CT. We hope it can get a more accurate prediction of postoperative residual pulmonary function to provide better management for clinical surgery.


Clinical Trial Description

1. Newly diagnosed and pre-therapeutic patients with primary lung cancer

2. Study sample: the optimal study sample is expected to be >50 cases

3. Inclusion criteria: age 30-80 years old; newly diagnosis of primary lung cancer with radiological or pathological evidence; SPECT/CT scan was performed before surgery; written and informed consent with signature before the study

4. Exclusion criteria: with other tumor in addition to primary lung caner; receive surgery prior to SPECT/CT scan; failed to complete preoperative and postoperative pulmonary function tests; failed to perform scans; pregnancy, lactation, and impaired renal or liver function; poorly controlled diabetes; poor compliance; contrary to the standard operating procedures; not suitable for clinical trials (for example with mental illness);

Study protocol:

1. Examination time

1. Preoperative lung function test was performed within a month prior to surgery

2. Preoperative pulmonary ventilation/perfusion SPECT/CT were performed within a month prior to surgery

3. Postoperative pulmonary function test as well as follow-up were performed within three months after surgery 2. Pulmonary function test including but not limited to: forced expiratory volume in 1s(FEV1), diffusing capacity carbon monoxide(DLCO), forced vital capacity(FVC), maximal voluntary ventilation (MVV), peak expiratory flow(PEFR), vital capacity(VC), total lung capacity(TLC) 3. Pulmonary ventilation/perfusion SPECT/CT imaging: acquisition protocol according to EANM guidelines for ventilation/perfusion scintigraphy. Part 1. Using Technegas for ventilation imaging and 99mTc-MAA for perfusion imaging.

4. Image analysis:

1. Ventilation / perfusion SPECT/CT data were registered, processed and reconstructed in GE Xeleris Workstation, quantitative measurements were using Q.lung software.

2. Results including ventilation / perfusion uptake and volume (in counts and mL and respective percentage) of each pulmonary lobar.

5. Data analysis:

1. Predicted postoperative FEV1 (as well as other pulmonary function values) were calculated according to the following formula:

FEV1 fore-v = FEV1 pre × (1- Volume%); FEV1 fore-cv = FEV1 pre × (1- Counts%v); FEV1 fore-cp = FEV1 pre × (1- Counts%p).

*fore-v represents predicted postoperative value using volume; fore-cv represents predicted postoperative value using ventilation uptake; fore-cp represents predicted postoperative value using perfusion uptake; pre represents preoperative pulmonary test value.

2. A graphical method of the Bland-Altman plot was used to compare FEV1 (as well as other pulmonary function values) obtained from predictions and post-operative measurements (with certain systematic and random errors). Intervals of agreement were drawn as the mean difference between predicted and measured values plus and minus 1.96 times the standard deviation of the differences. Strength of linear relationship between predicted and measured FEV1 values was quantified by the Pearson correlation coefficients with significance based on t-statistics. P < 0.05 is statistically significant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03357094
Study type Observational
Source Beijing Tongren Hospital
Contact wang shuang, master
Phone 010-58268056
Email wangs198801@126.com
Status Recruiting
Phase N/A
Start date September 30, 2017
Completion date November 1, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05543954 - 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients Early Phase 1
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Active, not recruiting NCT02514512 - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking N/A
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02531737 - Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer Phase 2
Active, not recruiting NCT02284633 - Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Completed NCT02106143 - RejuvenAir™ System Lobectomy Safety and Histology Study N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Enrolling by invitation NCT01687647 - Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure Phase 3
Completed NCT00243685 - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase 2/Phase 3
Completed NCT00351962 - Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours N/A
Completed NCT00385177 - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors Phase 1
Terminated NCT00356525 - Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor Phase 2
Completed NCT00129844 - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer Phase 2
Withdrawn NCT00090701 - A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT01789229 - Establishment of a Tumor Bank for Tissue Samples
Completed NCT00069160 - Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer Phase 2